Last updated: February 5, 2026
Case Overview
Orexo AB filed patent infringement litigation against Actavis Elizabeth LLC in the U.S. District Court for the District of Delaware. The case pertains to U.S. Patent No. 9,708,513 (the '513 patent), which claims formulations related to buprenorphine and naloxone for sublingual administration.
Core Allegations
Orexo alleges Actavis marketed a generic version of Zubsolv before patent expiration, infringing the '513 patent. The patent covers specific formulations designed to improve bioavailability and stability, with claims targeting the sublingual form of buprenorphine/naloxone.
Key Patent Claims
- The '513 patent claims formulations with particular ratios of buprenorphine to naloxone.
- Emphasizes a quick-dissolving sublingual dosage form.
- Describes specific excipient compositions for optimizing absorption.
Legal Proceedings and Major Developments
- The complaint was filed in early 2017.
- Orexo sought declaratory judgment of patent infringement and injunctive relief.
- Actavis filed a paragraph IV certification, challenging the patent's validity, triggering a 30-month stay under the Hatch-Waxman Act unless litigation resolved sooner.
- Throughout 2018-2019, the parties engaged in extensive patent claim construction proceedings.
- The case included motions to dismiss and summary judgment filings focusing on patent validity and infringement.
Patent Validity Challenges
- Actavis contested the patent's inventive step, arguing prior art disclosed similar formulations.
- The validity угр was supported by references to earlier drugs with comparable ratios and compositions.
- Orexo maintained the patent met statutory criteria, emphasizing distinctive features such as specific excipient ratios that enhance sublingual absorption.
Infringement Arguments
- Orexo alleged that Actavis's generic product embodied the patented formulation, especially regarding the ratio of active ingredients.
- Evidence included comparative formulation data and bioequivalence studies.
Court's Ruling and Outcomes (as last available)
- No final judgment issued; case was ongoing as of the last update.
- The district court had scheduled trial for 2020 but proceedings were delayed due to settlement discussions and COVID-19 disruptions.
- As of the latest information, the case remained active, with potential settlements or court rulings slated for future dates.
Implications for Industry
- The case exemplifies disputes over formulation patents in the opioid addiction treatment market.
- Highlights the strategic importance of patent claims focused on excipient compositions and bioavailability.
- Reflects the legal complexities surrounding ANDA litigation, including validity defenses based on prior art and obviousness.
Analysis Highlights
- The litigation underscores the evolving landscape of patent protection for complex drug formulations.
- Effective patent drafting must clearly delineate inventive features that are not anticipated or obvious.
- Court decisions hinge heavily on claim construction and the strength of prior art references.
- Active patent enforcement can delay market entry for generics, impacting pricing and access.
Key Takeaways
- Litigation remains unresolved; settlement or court ruling pending.
- Patent claims focusing on formulation specifics can withstand challenges if properly supported.
- Prior art references pose significant validity threats but can be countered with detailed patent disclosures.
- Cases like these influence future formulation patent strategies and generic market entry timing.
FAQs
-
What does the '513 patent protect?
It covers specific buprenorphine/naloxone formulations, emphasizing ratios and excipient compositions for sublingual administration.
-
Why did Actavis challenge the patent’s validity?
They argued prior art disclosed similar formulations, questioning inventive step and non-obviousness.
-
How does paragraph IV certification impact the case?
It triggers a 30-month stay under the Hatch-Waxman Act while litigation proceeds, delaying generic market entry.
-
What are common patent defenses in such litigations?
Prior art references, obviousness arguments, and claim indefiniteness challenges.
-
What is the potential impact on the opioid treatment market?
Litigation delays generic entry, affecting drug prices and access for patients.
Sources
[1] Court filings, dockets, and publicly available case summaries.
